Citadel Advisors
SLDB icon

Citadel Advisors’s Solid Biosciences SLDB Stock Holding History

Citadel Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$236K Buy
32,800
+10,500
+47% +$67.5K ﹤0.01% 11050
2025
Q4 		$126K Buy
22,300
+7,400
+50% +$40.1K ﹤0.01% 11458
2025
Q3 		$91.9K Sell
14,900
-16,900
-53% -$98.8K ﹤0.01% 11894
2025
Q2 		$155K Buy
31,800
+1,600
+5% +$5.66K ﹤0.01% 10926
2025
Q1 		$112K Sell
30,200
-19,200
-39% -$82.2K ﹤0.01% 11308
2024
Q4 		$198K Sell
49,400
-7,800
-14% -$42.8K ﹤0.01% 10483
2024
Q3 		$399K Buy
57,200
+52,900
+1,230% +$429K ﹤0.01% 8725
2024
Q2 		$24.4K Sell
4,300
-5,400
-56% -$48.4K ﹤0.01% 12461
2024
Q1 		$129K Buy
+9,700
New +$90.8K ﹤0.01% 10989
2023
Q2 		– Sell
-6
Closed -$28 – 15141
2023
Q1 		$28 Buy
+6
New +$36 ﹤0.01% 14615
2022
Q4 		– Sell
-1,753
Closed -$12K – 15405
2022
Q3 		$12K Buy
1,753
+106
+6% +$1.07K ﹤0.01% 12234
2022
Q2 		$15K Buy
1,647
+140
+9% +$1.46K ﹤0.01% 12498
2022
Q1 		$27K Buy
+1,507
New +$26.6K ﹤0.01% 13153
2021
Q4 		– Sell
-1,853
Closed -$66K – 14679
2021
Q3 		$66K Sell
1,853
-940
-34% -$39.9K ﹤0.01% 13200
2021
Q2 		$153K Sell
2,793
-2,200
-44% -$145K ﹤0.01% 12485
2021
Q1 		$414K Sell
4,993
-1,047
-17% -$116K ﹤0.01% 10094
2020
Q4 		$687K Buy
+6,040
New +$382K ﹤0.01% 7540
2020
Q3 		– Sell
-2,373
Closed -$104K – 10672
2020
Q2 		$104K Sell
2,373
-1,854
-44% -$77K ﹤0.01% 8969
2020
Q1 		$152K Sell
4,227
-3,193
-43% -$158K ﹤0.01% 8282
2019
Q4 		$495K Sell
7,420
-1,853
-20% -$204K ﹤0.01% 6820
2019
Q3 		$1.44M Buy
9,273
+6,486
+233% +$734K ﹤0.01% 4994
2019
Q2 		$240K Sell
2,787
-873
-24% -$95.2K ﹤0.01% 7925
2019
Q1 		$505K Buy
+3,660
New +$917K ﹤0.01% 6772

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Citadel Advisors's SLDB Position: Q1 2026 in Review

Citadel Advisors reduced its Solid Biosciences (SLDB) stake by 2.5% in Q1 2026, selling an estimated $431K and leaving 2,596,800 shares worth $18.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2404.

Citadel Advisors first reported a position in SLDB in Q1 2018 and has held it in 25 quarters since. 150 funds tracked by Wall St. Rank hold SLDB as of Q1 2026.

  • Citadel Advisors held 2,596,800 shares of Solid Biosciences worth $18.7M as of Q1 2026.
  • Citadel Advisors sold 67,063 Solid Biosciences shares in Q1 2026, an estimated $431K.
  • Solid Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2404 holding.
  • Citadel Advisors first reported a position in Solid Biosciences in Q1 2018 and has held it in 25 quarters since.
  • 150 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.